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Vaccination produces profound and long lasting modiIca-
tions in the adaptive immune system comprising T and
B cells. Vaccines are curative not mere palliative remedies
and thus vaccination is the most eMcient method to pre-
vent and to lesser extent treat infectious diseases, cancer,
and allergy conditions. Currently, there is an increasing
interest in developing vaccines based on synthetic peptides
encompassing B and T cell epitopes that precisely trigger a
protective immune response. Because they are synthetic, pep-
tide vaccines are intrinsically safer than alternative vaccine
formulations. Moreover, peptide-based vaccines will allow
focusing solely on relevant epitopes, avoiding those that lead
to nonprotective responses, immune evasion, or unwanted
side ePects, such as autoimmunity. However, developing
a successful peptide-based vaccine requires addressing a
number of signiIcant diMculties, such as overcoming the low
intrinsic immunogenicity of individual peptides. In this spe-
cial issue on peptide-based vaccines, we have incorporated 9
original articles and two reviews that deal with and examine
various aspects of peptide-based vaccine design.
Be review by H. Kimura et al. oPers new insights
into the function of the immunoproteasome in immune
and nonimmune cells. Cleavage of intracellular proteins by
immunoproteasome is a key step on the MHC class I antigen
presentation pathway and this review highlights the relevance
of understanding immunoproteasome function for devel-
oping peptide-based vaccines and novel pharmacological
treatments. Be second review by Y.-F. Xiao et al. oPers an
outstanding analysis on peptide-based treatments for cancer.
Be authors divide peptide-based cancer treatments into
three types, peptide-alone therapy, peptide vaccines, and
peptide-conjugated nanomaterials, describing new advances
in using peptides to treat lung, pancreatic, prostate, and gas-
tric cancers. Moreover, the authors masterly collect evidence
on how peptides represent ideal tumor immunotherapeutics
as one can speciIcally target tumor cells with little toxicity
and eMcient immunoreaction.
Be original articles incorporated in this issue consist of
cutting-edge computational and experimental reports that
are relevant for the design of peptide-based vaccines. Within
the in silico manuscripts, we include a work by D. Kanduc
et al. in which the authors compared the proteome of
poliovirus with that of humans and found unique poliovirus
peptide sequences that could be basis for developing a spe-
ciIc/universal vaccine, with no cross-reactions with human
proteins. As an additional advantage, the authors argue that
a peptide-based vaccine instead of current antipolio DNA
vaccines would eliminate the rare postpoliomyelitis cases
and other disabling symptoms that may appear following
vaccination. Computer-assisted design of peptide-based vac-
cines o^en relies on more complex predictive models to
select peptide fragments within antigens containing T and B
cell epitopes. Generation of predictive models requires the
assembling of categorized datasets for training the models.
Dataset assembly is labor intense and time consuming. S.
C. Pro et al. have masterly addressed the problem, devising
a method to automate the generation of validated speciIc
epitope sets from the IEDB database (http://www.iedb.org/).
Be availability of the disease-speciIc sequence data enables
the use of predictive tools that reveal entire epitomes thus
facilitating the development of epitope-based vaccines. How-
ever, in large and complex pathogens the potential T cell
epitome can be so sizeable that it will challenge experimental
validation. To address this problem M. Molero-Abraham
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et al. report a method and resource, EPIPOX, that allows
downsizing the relevant T cell epitome for variola virus
according to conservation criteria and antigen features such
as expression and localization.
Be experimental articles contained in the issue have
a wide scope and include a phase II clinical trial by S.
Yutani et al. Be study is based on a personalized peptide
vaccination with both a hepatitis C virus- (HCV-) derived
peptide and peptides from tumor-associated antigens (TAA)
for the treatment of HCV-positive advanced hepatocellular
carcinoma patients. Be authors show that the peptide-
based vaccine (PPV) was safe and elicited HCV speciIc
CTL responses as well as peptide-speciIc IgG1 responses to
both the viral peptides and TAA-derived peptides supporting
further clinical study of PPV. IdentiIcation of the antigens
that are targeted by the immune system and characterizing
the type of response are clearly a step forward towards
designing a useful peptide-based vaccine. In this context,
M. Niki et al. present an evaluation of humoral immu-
nity to Mycobacterium tuberculosis- (TB-) speciIc antigens
concluding that the induction of antigen-speciIc humoral
immunity, especially for IgA response, is relevant for TB pro-
tection. Similarly, A. N. Kamali et al. show that Plasmodium
antigens isolated by antibody aMnity of sera from malaria-
self-resistant ICR mice are capable of delaying infection
when inoculated into BALB/c mice. Bereby, the authors
conclude that immunoaMnity puriIed antigens using IgGs
from protected individuals can be relevant for developing
multiantigen blood-stage malaria vaccines. Vaccine develop-
ment and optimization require Inding appropriated animal
models for testing. In this issue, I. Sominskaya et al. show that
rabbits are suitable animalmodels to test the immunogenicity
of core peptides from hepatitis C virus, promoting the use of
rabbit models for preclinical trials of HCV vaccines.
Peptides exhibit little immunogenicity and thereby it is
key to devise means of increasing their immunogenicity for
vaccine design purposes. In this issue, A. Yano et al. show
that combining amyloid beta (A훽) peptides with toxoid (DT)
enhanced the immunogenicity of the peptide on cynomolgus
monkeys and guinea pigs that were Irst immunized with
conventional diphtheria-tetanus. Moreover, the peptide vac-
cine induced anti-A훽 antibodies in cynomolgus monkeys
and guinea pigs without chemical adjuvants, and excessive
immune responses were not observed. Peptides can also have
immunomodulatory properties as shown in the article by J.-P.
Vernot et al., in which the authors show that it is possible to
modulate p56Lck in T cells by a chimeric peptide comprising
two functionally diPerent motifs of Tip from Herpesvirus
saimiri.
In conclusion, this special issue surveyed many aspects of
peptide-based vaccines and we hope readers will Ind it both
interesting and inspiring. It certainly has been a pleasure for
us to select the work presented in this issue.
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